Clinical Trials Logo

Head Cancer clinical trials

View clinical trials related to Head Cancer.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06395805 Recruiting - Head Cancer Clinical Trials

Evaluation of Quality of Life and Self-assurance and Social Support Earned for Non-cellular Head Cancer

Start date: June 15, 2023
Phase:
Study type: Observational

Research objectives: - To evaluate the quality of life of patients before and after surgery for benign head tumors ( meningiomas) and malignant tumors at stage I, II and III, to assess whether it depends on the size of the tumor, type of tumor, malignancy and its location - evaluation of the independence of patients before and after surgery for head tumors at different stages of the disease - benign tumors (meningiomas) and malignant tumors in stage I, II and III, evaluation of what factors affected the different independence of patients - Multidimensional evaluation of perceived social support of patients before and after surgery for head cancers - benign ( meningiomas) and malignant tumors in stage I, II and III, taking into account three sources of support: significant person, family and friends Scientific (research) problems: - What is the quality of life of patients before and after surgery for benign ( meningiomas) and malignant head cancers at stages I, II and III ? Is quality of life in patients with head cancer dependent on tumor size, malignancy, location or type of cancer ?

NCT ID: NCT05549414 Recruiting - Brain Cancer Clinical Trials

Pivotal Study of Proton Radiotherapy Treatments Using Fixed Beam Chair-Based Delivery System

PPTS
Start date: March 30, 2023
Phase: N/A
Study type: Interventional

This study with Chair-Based, Gantry-less Proton System (CBGS) (aka P-CURE Proton Beam Therapy System or Fixed Beam Chair-based Delivery System) is composed of 3 arms, as following: ARM1: Patients with locally recurrent, previously irradiated thoracic cancer indicated for re- irradiation. ARM2: Patients with recurrent Head and Neck, Brain and Spinal Cord tumors, indicated for re- irradiation. ARM3: Patients with unresectable pancreatic cancer. The primary objectives of the study for all arms are: 1. to describe the efficacy (local control after 3 month) and acute toxicity for patients treated with a fully-integrated CBGS and (2) to compare treatment plans between the fully-integrated CBGS and Photon therapy defined for each patient, based upon OAR sparing for comparable target coverage.

NCT ID: NCT05420948 Recruiting - Clinical trials for Head and Neck Cancer

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

Start date: October 17, 2022
Phase: Phase 2
Study type: Interventional

By doing this study, the research team would like to learn if using a blood test that measures the amount of tumor DNA in blood can help guide how to use chemotherapy combined with immunotherapy for individuals with head and neck cancer. Using this blood test, the research team hopes to learn if intermittent (occasional) chemotherapy added to immunotherapy will work better than immunotherapy alone. Participation in this research will last about two years.

NCT ID: NCT04750434 Recruiting - Neck Cancer Clinical Trials

PET MRI as a Staging Tool for Head and Neck Cancer

Start date: March 3, 2020
Phase:
Study type: Observational

To explore the use of PET/MRI in the staging and pretreatment evaluation of patients with head and neck cancer and to compare this modality to standard PET/CT imaging.

NCT ID: NCT04722523 Recruiting - Clinical trials for Head and Neck Cancer

A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer

Start date: January 20, 2021
Phase: Phase 1
Study type: Interventional

The purpose of this study is to find out whether combining the standard chemotherapy for head and neck cancer with the immunotherapy drugs cetuximab and cemiplimab (the study drug) is a safe treatment for head and neck cancer, and whether receiving this combination treatment before surgery may allow participants to forgo the standard radiation treatment after surgery.

NCT ID: NCT04673981 Recruiting - Chronic Pain Clinical Trials

Neurosensorial Disorder and Pain in Oral Cavity and Oropharynx Cancer Traited Patients (OCAPA)

OCAPA
Start date: July 31, 2020
Phase: N/A
Study type: Interventional

Following preliminary studies carried out in our department on these subject and subjective findings during clinical examinations, it has been shown that pain is a symptom that is rarely reported following treatment. Instead, neurosensory disorders such as hypoesthesia and paresthesia are found. The objective of the study is to map and qualitatively evaluate neurosensory disorders in patients treated for cancers of the oral cavity and oropharynx.

NCT ID: NCT03809208 Recruiting - Oral Cancer Clinical Trials

Birinapant and Intensity Modulated Re-Irradiation Therapy for Local-Regionally Recurrent Head and Neck Squamous Cell Carcinoma

Start date: April 15, 2019
Phase: Phase 1
Study type: Interventional

Background: Head and neck cancer is a group of cancers that start in the mouth, nose, throat, larynx and sinuses. The usual treatment is surgery, radiation, chemotherapy, or a combination of those. Approximately 50% of HPV-negative head and neck cancer patients that have been treated with any of these modalities will have a recurrence. For these patients, current treatment options include surgery and re-irradiation with chemotherapy, which can reduce symptoms and may stop the tumor from growing but in the majority of cases, only for a few months. In this trial, researchers want to see if they can cure or significantly lower the chance of head and neck cancer growing back or spreading by adding the new agent birinapant to re-irradiation. Objective: To test the safety of birinapant and re-irradiation at different doses in patients with head and neck cancer. Eligibility: Adults age 18 and older with head and neck cancer who are candidates for re-irradiation. Design: Participants will be screened with a review of their medical record. Participants will have exams and procedures that are part of their usual care. Participants will also have a test of heart activity before treatment. Participants will have urine pregnancy tests, if female. Participants will have blood and tumor samples taken 2 times and stored for research. The study lasts 6 weeks. Participants will get radiation for 5 days a week (Monday Friday) for all 6 weeks. Participant will get the study drug on 4 Tuesdays. They will get it in an arm vein over 30 minutes each time. About 4 weeks after the study ends, participants will have a follow-up visit. They will have a physical exam, health questions, and blood tests. Participants may have scans 4 times over the next 2 years. Participants will get an email or phone call every 6 months. Sponsoring Institute: National Cancer Institute